|
Tue, 02/18/2025 - 18:53 |
Foundation Medicine Collaborates with Sumitomo Pharma America to Advance Investigational Treatment for Patients with Acute Leukemia with NPM1 Mutations or KMT2A Rearrangements Using the FoundationOneHeme Platform |
|
Tue, 02/04/2025 - 18:45 |
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOneGermline and FoundationOneGermline More, in the United States Through a Partnership with Fulgent Genetics |
|
Fri, 01/17/2025 - 19:17 |
U.S. Food and Drug Administration Approves FoundationOneCDx as a Companion Diagnostic for OJEMDA (tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients |
|
Wed, 05/29/2024 - 16:28 |
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator |
|
Sat, 05/25/2024 - 11:00 |
Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO Annual Meeting |
|
Thu, 05/23/2024 - 00:47 |
Foundation Medicine Launches RNA Sequencing Test, FoundationOneRNA, in the U.S. |
|
Tue, 12/20/2022 - 19:02 |
Foundation Medicine Receives FDA Approval for FoundationOneLiquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients |
|
Mon, 11/14/2022 - 16:27 |
Foundation Medicine Launches FoundationReport+, a New Digital Reporting Experience to Streamline Precision Cancer Care |
|
Tue, 09/20/2022 - 21:48 |
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care |
|
Mon, 09/12/2022 - 23:56 |
Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic Profiling to Advance Cancer Care |
|
Sun, 09/11/2022 - 21:31 |
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOneCDx as a Companion Diagnostic for Relays Investigational FGFR2 Inhibitor, RLY-4008 |
|
Wed, 06/08/2022 - 19:37 |
U.S. FDA Approves FoundationOneCDx as a Companion Diagnostic for Rozlytrek (entrectinib) |
|
Sat, 06/04/2022 - 23:06 |
Foundation Medicine Announces Strategic Collaboration with Arvinas |
|
Fri, 06/03/2022 - 01:46 |
Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy |
|
Thu, 03/17/2022 - 08:36 |
U.S. FDA Approves FoundationOneCDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer |
|
Mon, 02/21/2022 - 18:41 |
U.S. FDA Approves FoundationOneCDx as a Companion Diagnostic for KEYTRUDA (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors |
|
Fri, 02/18/2022 - 05:05 |
Foundation Medicines ctDNA Monitoring Assay, FoundationOneTracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration |
|
Tue, 02/08/2022 - 22:58 |
Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOneCDx and FoundationOneLiquid CDx as Companion Diagnostics for RETEVMO and Loxo Oncology at Lillys Pipeline Programs |
|
Wed, 12/08/2021 - 14:25 |
FoundationOneCDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma |
|
Thu, 10/28/2021 - 08:33 |
Foundation Medicine Now an In-Network Provider for Humana Military and Health Net Federal Services |
|
Wed, 10/13/2021 - 02:02 |
Foundation Medicine Appoints Dymeka Harrison as Chief Commercial Officer |
|
Tue, 09/21/2021 - 09:51 |
Foundation Medicine Appoints Mia Levy, MD, PhD as Chief Medical Officer |
|
Wed, 09/08/2021 - 11:01 |
Science 37 and Foundation Medicine Partner to Enable Interventional Home-Based Clinical Trials in Oncology |
|
Thu, 08/26/2021 - 10:58 |
Foundation Medicine Announces Partnership With Epic to Streamline Access to Genomic Insights for Precision Cancer Care |
|
Wed, 08/04/2021 - 11:55 |
Foundation Medicine Appoints Sanket Agrawal as Chief BioPharma Business Officer |
|
Thu, 06/24/2021 - 09:37 |
Foundation Medicine Collaborates on Research Published in The New England Journal of Medicine That Identifies Resistance to KRAS Inhibitors and Underscores Need for Novel Therapeutic Strategies |
|
Tue, 06/08/2021 - 11:04 |
New Study Results Presented by Foundation Medicine and Collaborators at ASCO21 on Ancestry-Based Disparities in Prostate Cancer Care Underscore Importance of Equitable Access to Precision Medicine Advances |
|
Tue, 06/08/2021 - 09:22 |
Foundation Medicine Launches FoundationOneTracker ctDNA Monitoring Assay for Research Use in Partnership with Natera |
|
Tue, 09/24/2019 - 06:13 |
Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring |
|
Mon, 08/05/2019 - 15:50 |
Foundation Medicine Names Priti Hegde, Ph.D., as Chief Scientific Officer |
|
Mon, 07/01/2019 - 16:42 |
Foundation Medicine Expands Indication for FoundationOneCDx as a Companion Diagnostic for LYNPARZA (Olaparib) |
|
Wed, 05/29/2019 - 02:21 |
Bayer And Foundation Medicine Announce Global Collaboration To Develop Next-generation Sequencing (NGS)-based Companion Diagnostics In Oncology |
|
Thu, 05/16/2019 - 03:40 |
Foundation Medicine and Collaborators to Present New Data at ASCO 2019 Further Supporting the Utility of Comprehensive Genomic Profiling (CGP) to Inform Precision Medicine in Advanced Cancer |
|
Mon, 01/07/2019 - 16:05 |
Foundation Medicine Announces Executive Leadership Transition |
|
Thu, 12/27/2018 - 18:40 |
Foundation Medicine Announces Regulatory Approval of FoundationOneCDx in Japan |
|
Wed, 10/17/2018 - 17:26 |
Foundation Medicine Announces Strategic Collaboration with Major Pharmaceutical Company |
|
Mon, 09/24/2018 - 16:45 |
Foundation Medicine Introduces FoundationOneLiquid, the Latest Advance in the Companys Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer |
|
Mon, 08/06/2018 - 18:22 |
Foundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy |
